【佳學基因靶向藥物基因檢測】奧希替尼對攜帶原發(fā)性 EGFR-T790M 突變的肺腺癌肺段切除術(shù)后對側(cè)多發(fā)磨玻璃結(jié)節(jié)有效
國內(nèi)腫瘤檢測指標機構(gòu)排行榜加密
這的藥物化治療及藥物選擇聽到《J Cardiothorac Surg》在 2022 Dec 19;17(1):324.發(fā)表了一篇題目為《Osimertinib showed efficacy on contralateral multiple ground-glass nodules after segmentectomy for lung adenocarcinoma harboring primary EGFR-T790M mutation: a case report and review of the literature》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Haijun Dong, Jianbin Zhang, Weiwei Min, Qibin Shen等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展,進一步強調(diào)了基因信息檢測與分析的重要性。這項研究報告了一個多發(fā)磨玻璃樣結(jié)節(jié)(mGGNs)合并原發(fā)EGFR T790M突變肺腺癌的病例,其對腫瘤診斷和治療有以下幾點啟示: 對于mGGNs的鑒別診斷具有參考價值,提醒需要與原發(fā)多發(fā)肺癌進行鑒別,結(jié)合病理和分子檢測進行確認。 對EGFR T790M突變陽性的肺腺癌患者,手術(shù)切除可能是賊佳治療選擇。 對于殘余mGGNs,可以繼續(xù)采用Osimertinib等EGFR-TKI目標治療。 不同病灶對EGFR-TKI治療反應存在異質(zhì)性,提示存在克隆進化或耐藥機制。 EGFR-TKI可作為mGGNs術(shù)后殘余病灶的有效治療手段,但需要進一步優(yōu)化治療策略。 該研究支持對肺癌進行基因檢測指導正確用藥的重要性,EGFR狀態(tài)預測EGFR-TKI療效。 總之,該研究通過一個典型病例闡明了EGFR突變陽性肺癌正確診治策略,也提出了mGGNs個體化治療的參考方案,對這類患者的臨床管理具有一定的指導意義。
腫瘤基因檢測及靶向藥物治療研究關(guān)鍵詞:
表皮生長因子受體酪氨酸激酶抑制劑 (EGFR-TKI),多發(fā)磨玻璃結(jié)節(jié) (mGGNs),同步多原發(fā)性肺癌 (SMPLC)。
腫瘤治療檢測基因臨床應用結(jié)果
靶向藥物研究立項的依據(jù):肺部多發(fā)磨玻璃結(jié)節(jié)(mGGNs)已被定義為同時性多原發(fā)性肺癌(SMPLC),SMPLC與肺內(nèi)轉(zhuǎn)移瘤的鑒別難度很大,其治療仍存在爭議。病例介紹:我們報道一例mGGNs與原發(fā)性EGFR-T790M突變肺腺癌同時發(fā)生,患者行左上肺病灶治好性切除,右肺各葉殘留mGGNs繼續(xù)奧希替尼治療。這些 mGGNs 對奧希替尼表現(xiàn)出不同的反應。藥物指導及病因判斷的依據(jù):我們報告了 mGGNs 術(shù)后治療的成功策略。對于無法有效切除的,則進行了化療、放療、立體定向放療、免疫治療和靶向治療。 EGFR-TKI治療策略顯示出顯著優(yōu)勢,但如何達到更好的治療效果還需要更多研究。關(guān)鍵詞:表皮生長因子受體酪氨酸激酶抑制劑(EGFR-TKI);多發(fā)磨玻璃結(jié)節(jié) (mGGNs);同步多原發(fā)性肺癌 (SMPLC)。
腫瘤發(fā)生與革命國際數(shù)據(jù)庫描述:
Background: Multiple ground-glass nodules (mGGNs) in the lung has been defined as synchronous multiple primary lung cancer (SMPLC), it is has been very difficult challenging to differentiate SMPLC from intrapulmonary metastases, and its treatment remains controversial.Case presentation: We report a case simultaneously involving mGGNs and lung adenocarcinoma harboring primary EGFR-T790M mutation, in which the patient underwent the radical resection of lesions in the left upper lung, and continued the osimertinib treatment for the residual mGGNs in all lobes of the right lung. These mGGNs displayed different responses to osimertinib.Conclusions: We reported a successful strategy on the postoperative treatment for mGGNs. For those that cannot be completely resected, the chemotherapy, radiotherapy, stereotactic body radiation therapy, immunotherapy and targeted therapy have been performed instead. The EGFR-TKI therapy strategy showed significant advantages, but how to achieve even better therapeutic effect needs more researches.Keywords: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI); Multiple ground-glass nodules (mGGNs); Synchronous multiple primary lung cancer (SMPLC).
(責任編輯:佳學基因)